AngioDynamics ANGO has been gaining from its solid prospects with NanoKnife and an increased focus on cancer treatment ...

AngioDynamics, Inc.’s ANGO investors have been experiencing some short-term losses from the stock of late. Shares of the Latham, NY-based medical technology company have plunged 13.8% in the past ...

AngioDynamics stock reacted positively to fiscal Q4 results, up over 25% in a day, as the company saw 8% sequential revenue growth and 14% growth from the Med Tech portfolio. Auryon and NanoKnife ...

AngioDynamics (ANGO) has been on a downward spiral lately with significant selling pressure. After declining 25% over the past four weeks, the stock looks well positioned for a trend reversal as it is ...

AngioDynamics beat on sales and beat on earnings this morning -- sort of. The company reported a smaller-than-expected adjusted loss, but its GAAP loss was much bigger. AngioDynamics lost money in ...

The medical technology company announced the retirement of CEO Jim Clemmer. This news creates uncertainty for AngioDynamics -- and investors dislike uncertainty. However, the company's business ...

AngioDynamics' fiscal Q2'25 results exceeded expectations, with Med Tech growing 25% and delivering better gross margins, boosting confidence in achieving high single-digit revenue growth and ...

AngioDynamics reported mixed fiscal 2025 Q1 results. The medical technology company has had some good news recently, though. AngioDynamics continues to expect modest growth for the full year.